fresenius se & co. kgaa - FSNUY

FSNUY

Close Chg Chg %
12.03 0.09 0.75%

Closed Market

12.12

+0.09 (0.75%)

Volume: 201.08K

Last Updated:

May 8, 2026, 3:53 PM EDT

Company Overview: fresenius se & co. kgaa - FSNUY

FSNUY Key Data

Open

$12.25

Day Range

12.00 - 12.44

52 Week Range

11.28 - 33.93

Market Cap

$27.04B

Shares Outstanding

2.25B

Public Float

N/A

Beta

0.56

Rev. Per Employee

N/A

P/E Ratio

15.85

EPS

$0.76

Yield

157.10%

Dividend

$0.20

EX-DIVIDEND DATE

May 26, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

149.56K

 

FSNUY Performance

1 Week
 
-0.90%
 
1 Month
 
-7.48%
 
3 Months
 
-19.79%
 
1 Year
 
-0.66%
 
5 Years
 
-4.19%
 

FSNUY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 14
Full Ratings ➔

About fresenius se & co. kgaa - FSNUY

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.

FSNUY At a Glance

Fresenius SE & Co. KGaA
Else-Kröner-Strasse 1
Bad Homburg, Hessen 61352
Phone 49-6172-608-0 Revenue 25.81B
Industry Hospital/Nursing Management Net Income 1.43B
Sector Health Services 2025 Sales Growth 9.305%
Fiscal Year-end 12 / 2026 Employees 178,394
View SEC Filings

FSNUY Valuation

P/E Current 15.848
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 22.712
Price to Sales Ratio 1.255
Price to Book Ratio 1.444
Price to Cash Flow Ratio 10.65
Enterprise Value to EBITDA 12.179
Enterprise Value to Sales 1.756
Total Debt to Enterprise Value 0.309

FSNUY Efficiency

Revenue/Employee 144,701.971
Income Per Employee 7,996.471
Receivables Turnover 3.786
Total Asset Turnover 0.551

FSNUY Liquidity

Current Ratio 1.315
Quick Ratio 1.004
Cash Ratio 0.189

FSNUY Profitability

Gross Margin 24.89
Operating Margin 9.522
Pretax Margin 8.70
Net Margin 5.526
Return on Assets 3.70
Return on Equity 8.125
Return on Total Capital 4.756
Return on Invested Capital 5.241

FSNUY Capital Structure

Total Debt to Total Equity 62.463
Total Debt to Total Capital 38.448
Total Debt to Total Assets 28.827
Long-Term Debt to Equity 54.763
Long-Term Debt to Total Capital 33.708
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Fresenius Se & Co. Kgaa - FSNUY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
42.71B 24.11B 23.62B 25.81B
Sales Growth
-2.55% -43.55% -2.04% +9.30%
Cost of Goods Sold (COGS) incl D&A
31.65B 18.64B 17.80B 19.39B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.08B 1.60B 1.30B 1.26B
Depreciation
- - - 2.52B
-
Amortization of Intangibles
- - - 563.32M
-
COGS Growth
-1.80% -41.11% -4.51% +8.93%
Gross Income
11.06B 5.47B 5.82B 6.42B
Gross Income Growth
-4.62% -50.55% +6.38% +10.45%
Gross Profit Margin
+25.89% +22.68% +24.63% +24.89%
2022 2023 2024 2025 5-year trend
SG&A Expense
7.94B 4.07B 3.83B 3.97B
Research & Development
884.92M 657.32M 693.36M 714.39M
Other SG&A
7.05B 3.41B 3.14B 3.25B
SGA Growth
+8.16% -48.76% -5.80% +3.54%
Other Operating Expense
- - - -
-
Unusual Expense
(86.18M) 112.44M 12.98M 48.53M
EBIT after Unusual Expense
3.21B 1.29B 1.97B 2.41B
Non Operating Income/Expense
403.57M 70.27M 74.64M 330.67M
Non-Operating Interest Income
194.43M 127.57M 122.23M 130.92M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
724.12M 572.99M 587.36M 494.32M
Interest Expense Growth
-3.06% -20.87% +2.51% -15.84%
Gross Interest Expense
724.12M 572.99M 589.52M 494.32M
Interest Capitalized
- - - 2.16M
-
Pretax Income
2.89B 785.97M 1.46B 2.25B
Pretax Income Growth
-31.40% -72.77% +85.79% +53.80%
Pretax Margin
+6.76% +3.26% +6.18% +8.70%
Income Tax
732.53M 515.69M 563.56M 656.83M
Income Tax - Current - Domestic
81.98M 120.00M 42.19M 153.49M
Income Tax - Current - Foreign
781.92M 411.91M 486.76M 529.30M
Income Tax - Deferred - Domestic
72.52M 63.79M 46.51M (40.63M)
Income Tax - Deferred - Foreign
(203.89M) (80.00M) (11.90M) 14.67M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
2.22B 257.31M 937.83M 1.81B
Minority Interest Expense
782.98M (124.33M) (189.30M) 79.00M
Net Income
1.44B 381.63M 1.13B 1.73B
Net Income Growth
-32.90% -73.53% +195.34% +53.80%
Net Margin Growth
+3.38% +1.58% +4.77% +6.72%
Extraordinaries & Discontinued Operations
- (1.02B) (617.65M) (306.97M)
Discontinued Operations
- (1.02B) (617.65M) (306.97M)
Net Income After Extraordinaries
1.44B (642.18M) 509.48M 1.43B
Preferred Dividends
- - - -
-
Net Income Available to Common
1.44B (642.18M) 509.48M 1.43B
EPS (Basic)
0.6423 -0.285 0.2261 0.6332
EPS (Basic) Growth
-33.27% -144.37% +179.33% +180.05%
Basic Shares Outstanding
2.25B 2.25B 2.25B 2.25B
EPS (Diluted)
0.6423 -0.285 0.2261 0.6332
EPS (Diluted) Growth
-33.27% -144.37% +179.33% +180.05%
Diluted Shares Outstanding
2.25B 2.25B 2.25B 2.25B
EBITDA
6.20B 3.00B 3.29B 3.72B
EBITDA Growth
-15.99% -51.67% +9.65% +13.19%
EBITDA Margin
+14.53% +12.44% +13.92% +14.42%

Snapshot

Average Recommendation BUY Average Target Price 16.42
Number of Ratings 14 Current Quarters Estimate 0.255
FY Report Date 06 / 2026 Current Year's Estimate 1.048
Last Quarter’s Earnings 0.241 Median PE on CY Estimate N/A
Year Ago Earnings 0.847 Next Fiscal Year Estimate 1.138
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 12 12
Mean Estimate 0.25 0.22 1.05 1.14
High Estimates 0.27 0.23 1.11 1.18
Low Estimate 0.22 0.19 0.91 1.02
Coefficient of Variance 8.44 10.39 4.84 4.37

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 10 11
OVERWEIGHT 3 3 2
HOLD 1 1 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Fresenius Se & Co. Kgaa in the News